B1Q.F NRx Pharmaceuticals, Inc.
- Market cap
- EUR 123M
- P/E
- -
- P/B
- 3.09x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is B1Q.F undervalued?
Graham numberThe Graham number of NRx Pharmaceuticals, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NRx Pharmaceuticals, Inc. fundamental analysis
No fundamental analysis for NRx Pharmaceuticals, Inc. yet.
NRx Pharmaceuticals, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation an…
Full company profileNRx Pharmaceuticals, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NRx Pharmaceuticals, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 1.23M | 4.34M |
| Gross Profit | - | - | - | 0.00 | 720K | 1.73M |
| Operating Income | -94.4M | -44.3M | -27.6M | -18.5M | -16.2M | -22.5M |
| EBITDA | - | -39.8M | -30.0M | -24.9M | -27.8M | -34.3M |
| Net Income | -93.1M | -39.8M | -30.2M | -25.1M | -28.6M | -35.9M |
| EPS | -16 | -5.98 | -3.59 | -1.72 | -0.90 | -0.83 |
| Balance Sheet | ||||||
| Total Assets | 32.7M | 25.8M | 7.32M | 3.65M | 13.0M | 34.2M |
| Total Liabilities | 11.9M | 18.4M | 19.0M | 26.9M | 28.9M | 34.3M |
| Shareholders' Equity | 20.8M | 7.41M | -11.7M | -23.2M | -15.9M | -170K |
| Cash & Short-term Investments | 27.6M | 20.1M | 4.60M | 1.44M | 7.80M | 26.7M |
| Cash Flow | ||||||
| Operating Cash Flow | -37.7M | -39.8M | -21.7M | -10.6M | -14.1M | -26.3M |
| Capital Expenditure | 7.00K | 10.0K | 3.00K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -37.7M | -39.8M | -21.7M | -10.6M | -14.1M | -28.1M |
| Ratios | ||||||
| ROE | -447.3% | -536.6% | - | - | - | - |
| ROA | -284.3% | -154.0% | -412.2% | -688.2% | -220.9% | -105.1% |
| Net Profit Margin | - | - | - | - | -2,336.5% | -827.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NRx Pharmaceuticals, Inc. dividends
NRx Pharmaceuticals, Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:10 on Apr 2, 2024.
Who owns NRx Pharmaceuticals, Inc.
- Insiders 4.08%
- Institutions 28.06%
- Public & others 67.85%
- Shares outstanding 43.3M
- Free float 37.4M
NRx Pharmaceuticals, Inc. company profile
- Company name
- NRx Pharmaceuticals, Inc.
- Ticker
- B1Q.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29
- Fiscal year end
- December
- Address
- 1201 N. Market Street, Wilmington, DE, United States, 19801
- Phone
- 484 254 6134
- Website
- nrxpharma.com
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
NRx Pharmaceuticals, Inc. management
3- Dr. Jonathan C. Javitt M.D., M.P.H.Co-Founder, Chairman & CEO · born 1957
- Mr. Michael S. Abrams M.B.A.CFO & Treasurer · born 1970
- Mr. Joseph M. CasperChief Operating Officer · born 1951